The American Society of Clinical Oncology (ASCO) has reviewed complications associated with immune checkpoint inhibitor therapy.
Patient selection: acquired hemophilia A following therapy with an immune checkpoint inhibitor
Parameters:
(1) Factor 8 activity in plasma
|
Factor 8 Plasma Activity
|
Grade
|
|
5 to 40% of normal
|
G1
|
|
1 to 5% of normal
|
G2
|
|
< 1% of normal
|
G3/G4
|
where:
• Each percent of normal activity can be expressed as 0.01 mIU/mL.
Clinical severity could be added as a parameter, with G4 showing life-threatening bleeding.
The diagnosis requires exclusion of:
(1) other causes of acquired hemophilia or von Willebrand's disease.
(2) hereditary hemophilia
